(Reuters) - European regulators said on Thursday they have completed their assessment of drug manufacturing violations at Ranbaxy Laboratories Ltd’s facility in Toansa, India, and although deficiencies were found, they pose no risk to public health.
The regulators said they were satisfied by corrective measures put in place by the company after U.S. regulators found deviations in January.
The assessment stands in stark contrast to the response of U.S. regulators to the deficiencies found at the plant. The Food and Drug Administration barred Ranbaxy from making and selling pharmaceutical ingredients from the Toansa facility “to prevent substandard quality products from reaching U.S. consumers.”
Ranbaxy is in the process of being acquired by Indian-based Sun Pharmaceutical Industries Ltd for $3.2 billion. In March the FDA banned imports from Sun’s plant at Karkhadi.
G.N. Singh, the Drugs Controller General of India, did not respond to a call for comment made after business hours, but some experts said they expect India to use the split between Europe and the United States to validate their claims that the U.S. is being too harsh on Indian drug companies.
“In that sense I see this as being very negative,” said Roger Bate, economist at the American Enterprise Institute. “It would have been far more useful if Europe and the U.S. had walked the same line.”
The U.S. ban on products from the Toansa facility is part of a broader crackdown by the U.S. regulator on substandard generic drugs from India. Toansa became the fourth Ranbaxy plant whose products were barred from the United States.
Following FDA’s Toansa inspection, European regulators sent a team of inspectors from Germany, Ireland and the United Kingdom, who were joined by inspectors from Switzerland and Australia, the European Medicines Agency (EMA) said.
“The inspection team concluded that there was no evidence that any medicines on the EU market that have an active pharmaceutical ingredient manufactured in Toansa were of unacceptable quality or presented a risk to the health of patients taking them,” the agency said.
“This conclusion was supported by tests of samples of these medicines, all of which met the correct quality specifications.”
Still, the EMA said European authorities “have identified the need to keep the Toansa site under close supervision and this will be done in collaboration with India and other regulatory authorities around the globe.”
A spokesman for Ranbaxy had no immediate comment.
The FDA said it will not lift its ban on Ranbaxy until it is satisfied the products meet quality standards.
“EMA and FDA inspected the Toansa facility using similar quality standards and underlying principles of current good manufacturing practices,” the FDA said in a statement. “Both regulators identified significant manufacturing and other violations that needed to be addressed, and both placed restrictions on the Toansa facility.”
While inspections were similar, the FDA said, the two regulatory authorities applied their own, differing, regulatory and legal standards to address the violations.
Reporting by Toni Clarke in Washington; additional reporting by Sumeet Chatterjee in Mumbai; Editing by Bill Trott and Diane Craft